2 results
Approved WMOCompleted
Cohort 1 (HER2-positive/amplified MBC): MCLA-128 + trastuzumab ± vinorelbine Primary objective:• Evaluate efficacy of MCLA-128 combined with trastuzumab ± vinorelbine in terms of clinical benefit rate (CBR) at 24 weeks based on RECIST 1.1 (per…
Approved WMOCompleted
The objective of this study is to assess the safety and effectiveness of the COVERATMObjectives: Vascular Covered Stent for the treatment of stenotic lesions in the upper extremityvenous outflow of the AV access circuit.